Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.93B$7.93Bderived+4.7% vs Q4 2024 Net Income$2.18B$2.18Bderived+22.4% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$1,984,000,000−19.1% Operating Cash Flowderived$3,327,000,000+11.8% Free Cash Flowderived$3,122,000,000+10.4% Margins · derivedOperating margin25.0%−7.4 pt vs Q4 2024
Net margin27.5%+4.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d after period end